Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated

Tectonic Therapeutic, Inc.

Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.
Phase 1b hemodynamic trial in PH-HFpEF escalated to 3 mg/kg IV; topline results expected Q2 2025.
Phase 2 APEX trial screening initiated; topline results anticipated in 2026.
Full Phase 1a results to be presented at AHA Scientific Sessions November 2024.
Over 600,000 patients estimated with Group 2 PH-HFpEF; no approved treatments currently.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.